Difference between revisions of "Paclitaxel (Taxol)"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m
m
Line 1: Line 1:
−
Also known as Onxal.
 
−
 
 
==General information==
 
==General information==
 
Class/mechanism: Taxane, promotes assembly of microtubules, stablizes microtubules, preventing depolymerization.  Paclitaxel interferes with the normal dynamic reorganization of microtubules that is necessary for regular interphase/mitosis processes.  It also leads to creation of abnormal bundles of microtubules.  Paclitaxel is highly lipophilic/insoluble in water and needs to be dissolved in Cremophor EL (polyoxyethylated castor oil), which may cause hypersensitivity infusion reactions.<ref name="insert">[http://packageinserts.bms.com/pi/pi_taxol.pdf Paclitaxel (Taxol) package insert]</ref><ref>[http://hemonc.org/docs/packageinsert/paclitaxel.pdf Paclitaxel (Taxol) package insert (locally hosted backup)]</ref>
 
Class/mechanism: Taxane, promotes assembly of microtubules, stablizes microtubules, preventing depolymerization.  Paclitaxel interferes with the normal dynamic reorganization of microtubules that is necessary for regular interphase/mitosis processes.  It also leads to creation of abnormal bundles of microtubules.  Paclitaxel is highly lipophilic/insoluble in water and needs to be dissolved in Cremophor EL (polyoxyethylated castor oil), which may cause hypersensitivity infusion reactions.<ref name="insert">[http://packageinserts.bms.com/pi/pi_taxol.pdf Paclitaxel (Taxol) package insert]</ref><ref>[http://hemonc.org/docs/packageinsert/paclitaxel.pdf Paclitaxel (Taxol) package insert (locally hosted backup)]</ref>
Line 7: Line 5:
  
 
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer.  Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref>  
 
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer.  Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref>  
 +
 +
==Diseases for which it is used==
 +
*[[Aggressive Non-Hodgkin lymphoma]]
 +
*[[Basal cell and squamous cell skin cancer]]
 +
*[[Bladder cancer]]
 +
*[[Breast cancer]]
 +
*[[Cervical cancer]]
 +
*[[Esophageal cancer]]
 +
*[[Head and neck cancer]]
 +
*[[Melanoma]]
 +
*[[Non-small cell lung cancer]]
 +
*[[Ovarian cancer]]
 +
*[[Penile cancer]]
 +
*[[Prostate cancer]]
 +
*[[Sarcoma]]
 +
*[[Small cell lung cancer]]
 +
*[[Testicular cancer]]
 +
*[[Thymoma]]
 +
*[[Unknown primary]]
 +
*[[Uterine cancer]]
  
 
==Patient drug information==
 
==Patient drug information==
Line 13: Line 31:
 
*[http://www.uptodate.com/contents/paclitaxel-patient-drug-information Paclitaxel (Taxol) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/paclitaxel-patient-drug-information Paclitaxel (Taxol) patient drug information (UpToDate)]</ref>
 
*[http://www.uptodate.com/contents/paclitaxel-patient-drug-information Paclitaxel (Taxol) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/paclitaxel-patient-drug-information Paclitaxel (Taxol) patient drug information (UpToDate)]</ref>
  
 +
==History of changes in FDA indication==
 +
* 12/29/1992: Initial FDA approval (label is not available)
 +
* 4/9/1998 (earliest label available on Drugs @ FDA): Indicated for:
 +
# First-line and subsequent therapy for the treatment of advanced [[Ovarian cancer | carcinoma of the ovary]]. As first-line therapy, Taxol is indicated in combination with [[Cisplatin (Platinol) | cisplatin]].
 +
# The treatment of [[Breast cancer | breast cancer]] after failure of combination therapy for metastatic disease or relapsed within 6 months of adjuvant chemotherapy. Prior therapy should have included an [http://hemonc.org/wiki/Category:Anthracyclines anthracycline] unless clinically contraindicated.
 +
# The second-line treatment of AIDS-related [[Sarcoma | Kaposi's sarcoma]].
 +
* 6/30/1998: New indication added: in combination with [[Cisplatin (Platinol) | cisplatin]], is indicated for the first-line treatment of [[Non-small cell lung cancer | non-small cell lung cancer]] in patients who are not candidates for potentially curative surgery and/or radiation therapy.
 +
* 10/25/1999: New indication for the adjuvant treatment of node-positive [[Breast cancer | breast cancer]] administered sequentially to standard [[Doxorubicin (Adriamycin) | doxorubicin]]-containing combination chemotherapy.
 +
 +
==Also known as==
 +
{| border="1" style="text-align:center;"
 +
!colspan="8" align="center" style="background-color:#0066FF"| '''Synonyms'''
 +
|-
 +
|Abitaxel
 +
|Altaxel
 +
|Anzatax
 +
|Anzatec
 +
|APO-Paclitaxel
 +
|Asotax
 +
|Betaxel
 +
|Bristaxol
 +
|-
 +
|Britaxol
 +
|Clitaxel
 +
|Cytax
 +
|Daburex
 +
|Dalys
 +
|Drifen
 +
|Ebetaxel
 +
|Formoxol
 +
|-
 +
|Genaxol
 +
|Genetaxyl
 +
|Gros
 +
|Ifaxol
 +
|Intaxel
 +
|LEP-ETU
 +
|LI PU SU
 +
|Magytax
 +
|-
 +
|Medixel
 +
|Mitotax
 +
|Neotacs
 +
|Neotaxan
 +
|Neotaxl
 +
|Ofoxel
 +
|Oncotaxel
 +
|Onxol
 +
|-
 +
|Paclitax
 +
|Paclitaxel
 +
|Paclitaxel-GRY
 +
|Paclitaxel APS
 +
|Paclitaxel Comp
 +
|Paclitaxel Delta Farma
 +
|Paclitaxel Ebewe
 +
|Paclitaxel Hexal
 +
|-
 +
|Paclitaxel Lens
 +
|Paclitaxel Mayne
 +
|Paclitaxel Microsules
 +
|Paclitaxel Servycal
 +
|Paclitaxin
 +
|Pacliteva
 +
|Pacxel
 +
|Padexol
 +
|-
 +
|Paklitaxfil
 +
|Panataxel
 +
|Parexel
 +
|Paxene
 +
|Paxenor
 +
|Paxus
 +
|Petaxel
 +
|Phyxol
 +
|-
 +
|Poltaxel
 +
|Praxel
 +
|Ribotax
 +
|Sindaxel
 +
|Taclipaxol
 +
|Tarvexol
 +
|Taxocris
 +
|Taxodiol
 +
|-
 +
|Taxol
 +
|Taxol Semi-Synthetic
 +
|Taxomedac
 +
|Taycovit
 +
|TE SU
 +
|Teva-Paclitaxel
 +
|Unitaxel
 +
|Yewtaxan
 +
|-
 +
|ZI SU
 +
|}
 
==References==
 
==References==
 
<references/>
 
<references/>
  
 +
[[Category:Drug index]]
 +
[[Category:Chemotherapy]]
 
[[Category:Irritant chemotherapy]]
 
[[Category:Irritant chemotherapy]]
 
[[Category:Vesicant chemotherapy]]
 
[[Category:Vesicant chemotherapy]]
Line 40: Line 156:
 
[[Category:Thymoma medications]]
 
[[Category:Thymoma medications]]
 
[[Category:Uterine cancer medications]]
 
[[Category:Uterine cancer medications]]
 +
 +
[[Category:Drugs FDA approved in 1992]]

Revision as of 14:55, 26 October 2014

General information

Class/mechanism: Taxane, promotes assembly of microtubules, stablizes microtubules, preventing depolymerization. Paclitaxel interferes with the normal dynamic reorganization of microtubules that is necessary for regular interphase/mitosis processes. It also leads to creation of abnormal bundles of microtubules. Paclitaxel is highly lipophilic/insoluble in water and needs to be dissolved in Cremophor EL (polyoxyethylated castor oil), which may cause hypersensitivity infusion reactions.[1][2]
Route: IV
Extravasation: irritant (usually), vesicant (rare)

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]

Diseases for which it is used

Patient drug information

History of changes in FDA indication

  • 12/29/1992: Initial FDA approval (label is not available)
  • 4/9/1998 (earliest label available on Drugs @ FDA): Indicated for:
  1. First-line and subsequent therapy for the treatment of advanced carcinoma of the ovary. As first-line therapy, Taxol is indicated in combination with cisplatin.
  2. The treatment of breast cancer after failure of combination therapy for metastatic disease or relapsed within 6 months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated.
  3. The second-line treatment of AIDS-related Kaposi's sarcoma.
  • 6/30/1998: New indication added: in combination with cisplatin, is indicated for the first-line treatment of non-small cell lung cancer in patients who are not candidates for potentially curative surgery and/or radiation therapy.
  • 10/25/1999: New indication for the adjuvant treatment of node-positive breast cancer administered sequentially to standard doxorubicin-containing combination chemotherapy.

Also known as

Synonyms
Abitaxel Altaxel Anzatax Anzatec APO-Paclitaxel Asotax Betaxel Bristaxol
Britaxol Clitaxel Cytax Daburex Dalys Drifen Ebetaxel Formoxol
Genaxol Genetaxyl Gros Ifaxol Intaxel LEP-ETU LI PU SU Magytax
Medixel Mitotax Neotacs Neotaxan Neotaxl Ofoxel Oncotaxel Onxol
Paclitax Paclitaxel Paclitaxel-GRY Paclitaxel APS Paclitaxel Comp Paclitaxel Delta Farma Paclitaxel Ebewe Paclitaxel Hexal
Paclitaxel Lens Paclitaxel Mayne Paclitaxel Microsules Paclitaxel Servycal Paclitaxin Pacliteva Pacxel Padexol
Paklitaxfil Panataxel Parexel Paxene Paxenor Paxus Petaxel Phyxol
Poltaxel Praxel Ribotax Sindaxel Taclipaxol Tarvexol Taxocris Taxodiol
Taxol Taxol Semi-Synthetic Taxomedac Taycovit TE SU Teva-Paclitaxel Unitaxel Yewtaxan
ZI SU

References

  1. ↑ 1.0 1.1 1.2 Paclitaxel (Taxol) package insert
  2. ↑ Paclitaxel (Taxol) package insert (locally hosted backup)
  3. ↑ Paclitaxel (Taxol) patient drug information (Chemocare)
  4. ↑ Paclitaxel (Taxol) patient drug information (UpToDate)
Retrieved from "https://hemonc.org/w/index.php?title=Paclitaxel_(Taxol)&oldid=5207"